CORT stock forecast, quote, news & analysis

Key Takeaways

• Corcept Therapeutics shares surged approximately 28.3% over the last 30 days, climbing from $72.62 to $93.16, driven by the resubmission of its New Drug Application for relacorilant in Cushing's syndrome.
• The stock has posted an extraordinary quarterly gain of roughly 123.5%, reflecting a powerful rally that began in early May following the Lifyorli approval in ovarian cancer and accelerating through June.
• Multiple analyst upgrades and price target increases—including a $135 target from UBS and Canaccord Genuity—fueled institutional buying and reinforced bullish sentiment.
• Presentation of compelling CATALYST and MOMENTUM trial data at the American Diabetes Association conference expanded the narrative around Korlym's addressable market in metabolic disorders.
• Insider selling and a Q1 earnings miss created brief headwinds, but pipeline momentum and regulatory catalysts overwhelmingly dominated price action.

Corcept Therapeutics (CORT) Company Overview and Market Position

Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on discovering and developing medications that modulate the effects of the hormone cortisol. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address severe endocrinologic, oncologic, metabolic, and neurologic disorders. Corcept's flagship product, Korlym (mifepristone), has been approved in the United States since 2012 for the treatment of hyperglycemia secondary to endogenous Cushing's syndrome. In 2026, the company expanded its commercial portfolio with the FDA approval of Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant ovarian cancer. With a market capitalization approaching $10 billion and a pipeline spanning Cushing's syndrome, solid tumors, ALS, and liver disease, Corcept has established itself as a leader in cortisol modulation therapy.

Corcept Therapeutics (CORT) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 calendar days, Corcept Therapeutics shares have climbed from a closing price of $72.62 on June 5, 2026, to $93.16 as of July 7, 2026—a gain of approximately 28.3%. The rally was not linear; the stock experienced a brief pullback in mid-June, dipping to $79.71 on June 22, before resuming its upward trajectory and setting a new 52-week high of $91.00 on July 1. The quarterly performance is even more striking. From a closing price of $41.69 on April 7, the stock has surged roughly 123.5%, reflecting a sustained re-rating as the market absorbed the significance of the Lifyorli approval, the relacorilant NDA resubmission, and expanding clinical evidence supporting cortisol modulation across multiple indications.

What Drove CORT Stock Price in the Last 30 Days

The dominant catalyst over the past 30 days was the June 17 resubmission of Corcept's New Drug Application to the FDA for relacorilant as a treatment for patients with Cushing's syndrome. The resubmission, which included additional analyses of existing clinical data as requested by the FDA, triggered a six-month review clock and removed a significant overhang that had weighed on the stock since the initial complete response letter. Investors reacted swiftly, sending shares sharply higher on heavy volume.

Earlier in the period, on June 6, Corcept presented new data from its CATALYST and MOMENTUM trials at the American Diabetes Association's 86th Scientific Sessions. The data demonstrated that patients with hypercortisolism and difficult-to-control type 2 diabetes treated with Korlym exhibited clinically meaningful improvements in HbA1c, body weight, and waist circumference—with numerically greater benefit observed in patients also taking GLP-1 receptor agonists. These findings expanded the perceived market opportunity for Korlym and reinforced the broader thesis around cortisol modulation.

Analyst activity provided additional fuel. HC Wainwright raised its price target from $75 to $95 on June 2, Truist Financial upgraded the stock to "strong-buy" on June 15, and UBS and Canaccord Genuity each set $135 price targets in late May. The stock also crossed above its 200-day moving average of approximately $52 in late June, triggering technical buying. Institutional inflows remained robust, with firms such as First Trust Advisors, AQR Capital Management, and JPMorgan Chase significantly increasing their positions during the first half of 2026.

What Drove CORT Stock Performance Over the Last Quarter

The quarterly rally that began in early April was ignited by a confluence of transformative events. The FDA approval of Lifyorli for platinum-resistant ovarian cancer marked Corcept's second approved product and validated the company's ability to expand beyond Cushing's syndrome. This was followed by the May 27 announcement that Corcept planned to resubmit the relacorilant NDA, which set the stage for the June resubmission. Positive CATALYST trial data published in Diabetes Care and presented at ADA further demonstrated that hypercortisolism is far more prevalent than previously believed—affecting 24% of patients with difficult-to-control type 2 diabetes and 27% of those with resistant hypertension—significantly expanding the addressable patient population for cortisol-modulating therapies. The combination of commercial execution, regulatory progress, and an expanding clinical narrative drove a fundamental re-rating of the stock, with the price more than doubling over the quarter.

Trending AI Robots

In a market environment where biotech stocks can experience rapid, data-driven price swings, traders are increasingly turning to AI-powered tools to identify opportunities and manage risk. Tickeron's Trending AI Robots page offers a curated selection of top-performing AI trading bots from a universe of hundreds that trade thousands of tickers across diverse strategies and timeframes. These bots are designed to analyze market patterns, technical signals, and fundamental data in real time, helping traders navigate volatile sectors like biotechnology with greater confidence. Only the most relevant and consistently performing bots appear in this section, making it a practical starting point for those looking to integrate algorithmic insights into their decision-making process. Explore the Trending AI Robots to see which strategies are currently resonating in the market.

CORT Stock Forecast Drivers: What Investors Should Watch Next

The most consequential near-term catalyst for Corcept Therapeutics is the FDA's decision on the relacorilant NDA for Cushing's syndrome, expected within approximately six months of the June 17 resubmission—pointing to a PDUFA date around December 2026. An approval would add a second major indication for relacorilant and significantly expand Corcept's endocrinology franchise. Investors should also monitor the commercial launch trajectory of Lifyorli in ovarian cancer, upcoming earnings reports for revenue growth and margin trends, and any further clinical data readouts from the company's pipeline programs in ALS, liver disease, and additional solid tumor indications. On the risk side, ongoing Korlym patent litigation, potential regulatory delays, and the possibility of further insider selling warrant attention. Macroeconomic factors affecting the biotech sector, including interest rate expectations and sector rotation dynamics, may also influence sentiment. As always, these factors should be evaluated within the context of individual investment objectives and risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations